Download presentation
Presentation is loading. Please wait.
Published byMavis Perkins Modified over 6 years ago
1
Detection and Management of Fever and Infection in the CICU
John T. Berger, MD Medical Director, Cardiac Intensive Care
2
Disclosures None Financial I am not an expert in infectious disease
The only infection I know anything about is critical pertussis
3
48,277 Cases 4994 < 1 year 20 deaths 16 < 1 year
4
Pulmonary Hypertension in Pertussis
PH seen in 75% of patient who died
5
Leukoreduction in Critical Pertussis
14 Patients (11%) Exchange transfusion (12), leukopheresis (1), both (1) 8 had pulmonary hypertension detected 4 had treatment on study day 0 No apparent survival benefit Patients with WBC Count > 50K by leukoreduction status Total Survivors Leukoreduction 13 8 No Leukoreduction 12 9
6
Objectives Outline the diagnostic dilemmas of nosocomial infection and fever Discuss the rise and fall of procalcitonin as biomarker for infection
7
Fever in the ICU Fever Prevalence 26-70%
Etiology equally split between infectious and noninfectious etiologies Prolonged fever more likely to be infection Fever a/w increased length of stay and possibly mortality 737 Adult ICU Patients In septic patients, NSAIDS/Acetaminophen a/w increased mortality (2-2.5 odds ratio) versus non-septic patients with reduced mortality risk (OR ) Lee et al. Crit Care 2012, 16:R33
8
Fever in the PICU PICU – Netherlands – 202 Children
40% with fever during ICU stay Only ½ with infection Most within 48 hours of admission Associated with increased PICU length of stay and mechanical ventilation Gordjin et al. J Int Care Med 2009
9
Fever ≠ Infection 3 mon old s/p TOF repair. Temp 38.8 C, WBC 15,000; CXR unchanged How many would send cultures on day 1 before exam? Blood, Urine, Tracheal Aspirate 66 post op febrile patients with blood cultures in 1st 48 hours 1 positive culture (staph epid) Kiragu PCCM :364 What about day 4? Fever “merits clinical assessment by a healthcare professional… prior to any laboratory tests or imaging procedures” Am College of Crit Care Med 2008
10
Sources of Fever Noninfectious Infectious Meningitis Brain Injury
Seizures CVA Meningitis Otitis Media Sinusitis Infarction Pulm Embolus ARDS Pericarditis Heart Failure CLA-BSI Endocarditis Ventilator associated LRTI Surgical Site Infection NEC CAUTI Pyelonephritis Perineal or perirectal abscess Pancreatitis Acalculous cholecystitis Ischemic colitis Drugs Transfusion Reactions Endocrine Disorders (Adrenal insufficiency, thyrotoxicosis) Malignancy Inflammatory disorders PICC or Femoral BSI Cellulitis Arthritis Pressure Ulcer DVT Drug Eruptions
11
Environment, Low cardiac output, & hyperthermia
Wyndham. Ann NY Acad Sci, 1977
12
Fever and Infection Adult Canadian (Calgary) ICUs CICU at CNMC
18,989 admissions Incidence of Fever fell from 50% to 25% No change in BSI rate, Abx consumption Niven et. al. CCM 2013, 41:1863 CICU at CNMC 1 CLABSI and 1 CAUTI in last year Still lots of antibiotic use
13
Infection Related Ventilator Associated Complications (IVACS) (A name only the CDC could love)
Most commonly diagnosed nosocomial infection in PICU Incidence varies / 1000 vent days Accounts for ½ antibiotic use in PICU Criteria for diagnosis neither sensitive or specific CDC: Infection a/w increase in vent settings (PEEP by 2 cm H20 or Fio2 by 0.2)
14
Would you send a tracheal aspirate? Start Antibiotics?
4 mo old with RSV intubated for 3 days. New 38.5 C fever, WBC =14,000, but no change on CXR 7 yo old intubated for 6 days for ARDS / near drowning. New fever (38.9), WBC = 13,000 and no CXR changes
15
Tracheal Aspirates for IVAC
Survey of 118 MDs in PALISI (98% Attending) 65% -obtained tracheal aspirates as part of a standard r/o sepsis work up 42% without a standard collection method “The RN or RT just does it” CXR unchanged. NO change in vent settings reported. Wilson PCCM 2014; 15:715
16
Percentage who would prescribe Antibiotics
IVAC Treatment Percentage who would prescribe Antibiotics RSV ARDS Gram Stain –Few PMN, Few GPC 34% 63% 2+MSSA, 2+PMN 79% 81% 2+MRSA, 2+PMN 91% 2+ Pseudomonas, 2+PMN 80% 87% CXR unchanged. NO change in vent settings reported. Wilson PCCM 2014; 15:715
17
Tracheal Aspirates 335 samples from 61 intubated PICU patients without regard for clinical status Predicted to be intubated for > 48 hours 42% post op CV surgery or cardiomyopathy None immunocompromised Culture results not provided to clinical team CDC Definition > 104 cfu/ml = positive Cx > 25 PMN / lpf Willson et. al. PCCM 2014; 15:299
18
TA do not discriminate between colonization and infection
In Line Suction 90% % Patients with > 25 PMN/lpf Single catheter 40% Willson et. al. PCCM 2014; 15:299
19
40-90% Positive Cultures CDC Clinical Criteria did not correlate with positive cultures Fever, WBCs, Increase Secretions, Worse oxygenation, CXR changes Typical Pathogens isolated Staph A, Stenotrophamonas, Neisseria, Klebsiella, and Staph E – 80% of cultures Willson et. al. PCCM 2014; 15:299
20
What to do? BIOMARKERS
21
Procalcitonin Precursor protein of Calcitonin
Usually undetectable in healthy humans Rises quickly in response to bacterial infection (IL-6, TNF-α) and less response in viral infection Initial studies suggested as method to guide diagnose infection Suggestions that it is better discriminator than CRP
22
Procalcitonin in PICU Single center study
64 of 225 eligible children with SIRS (25 with bacterial infection) PCT and CRP drawn when found to have SIRS Infection adjudicated by blinded investigators Compared CRP to PCT 2.5 ng/ml PCT threshold Simon PCCM 2008
23
Procalcitonin Variability
High Inter-patient variability Increases seen with cardiopulmonary bypass and other inflammatory states Use shifted to guide abx therapy Schuetz et al. Curr Opin CCM 2013
24
Procalcitonin after Cardiac Surgery
53 patients –All > 3 months, None Infected All significantly elevated for 3 days Michalik Card in the Young 2006
25
Conclusions Fever common problem
Diagnosis of infectious etiologies not as straightforward as waiting for culture results Antibiotic stewardship and rational discontinuation remain important awaiting the application of new biomarker strategies
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.